Q2 EPS Estimates for Legend Biotech Lifted by HC Wainwright

Legend Biotech Co. (NASDAQ:LEGN - Free Report) - Investment analysts at HC Wainwright boosted their Q2 2025 earnings estimates for Legend Biotech in a research note issued on Wednesday, May 14th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of $0.36 for the quarter, up from their prior estimate of $0.12. HC Wainwright has a "Buy" rating and a $75.00 price target on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech's Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at $0.22 EPS, FY2025 earnings at ($0.08) EPS, Q1 2026 earnings at $0.08 EPS, Q2 2026 earnings at $1.08 EPS, Q3 2026 earnings at $0.36 EPS and Q4 2026 earnings at $0.66 EPS.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.33. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The company had revenue of $195.05 million during the quarter, compared to the consensus estimate of $190.83 million. During the same quarter last year, the firm posted ($0.16) EPS. The company's quarterly revenue was up 107.8% on a year-over-year basis.

A number of other analysts have also recently weighed in on LEGN. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $55.00 target price on shares of Legend Biotech in a research note on Wednesday, May 14th. Guggenheim reiterated a "neutral" rating on shares of Legend Biotech in a report on Wednesday, March 12th. Truist Financial lowered their target price on shares of Legend Biotech from $88.00 to $71.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Royal Bank of Canada reiterated an "outperform" rating and issued a $84.00 price objective on shares of Legend Biotech in a research note on Tuesday, April 22nd. Finally, Morgan Stanley lowered their price target on shares of Legend Biotech from $82.00 to $80.00 and set an "overweight" rating on the stock in a report on Monday, March 17th. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $74.73.

Legend Biotech Price Performance

Shares of Legend Biotech stock opened at $27.78 on Monday. The company has a 50-day simple moving average of $33.47 and a two-hundred day simple moving average of $35.73. The stock has a market capitalization of $5.10 billion, a price-to-earnings ratio of -29.24 and a beta of 0.20. The company has a quick ratio of 4.90, a current ratio of 4.98 and a debt-to-equity ratio of 0.27. Legend Biotech has a twelve month low of $27.34 and a twelve month high of $60.87.

Hedge Funds Weigh In On Legend Biotech

A number of large investors have recently added to or reduced their stakes in LEGN. GAMMA Investing LLC raised its position in Legend Biotech by 145.4% in the 1st quarter. GAMMA Investing LLC now owns 1,291 shares of the company's stock worth $44,000 after purchasing an additional 765 shares during the period. Quarry LP purchased a new position in Legend Biotech in the 1st quarter worth $48,000. Signaturefd LLC raised its position in Legend Biotech by 1,052.7% in the 4th quarter. Signaturefd LLC now owns 1,729 shares of the company's stock worth $56,000 after purchasing an additional 1,579 shares during the period. GF Fund Management CO. LTD. purchased a new position in Legend Biotech in the 4th quarter worth $56,000. Finally, Brooklyn Investment Group raised its position in Legend Biotech by 1,114.8% in the 1st quarter. Brooklyn Investment Group now owns 1,725 shares of the company's stock worth $59,000 after purchasing an additional 1,583 shares during the period. Hedge funds and other institutional investors own 70.89% of the company's stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.